The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 3, 2010, Pages 762-770

  Caldarone, Barbara J ^a   Paterson, Neil E ^a   Zhou, Jia ^a   Brunner, Daniela ^a,b   Kozikowski, Alan P ^c   Westphal, Koen G C ^d   Korte Bouws, Gerdien A H ^d   Prins, Jolanda ^d   Korte, S Mechiel ^d   Olivier, Berend ^d   Ghavami, Afshin ^a  

^a PSYCHOGENICS INC   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 2 [4 (4 CHLOROPHENYL) 1 METHYLPIPERIDIN 3 YLMETHYLSULFANYL] 1 (3 METHYLPIPERIDIN 1 YL) ETHANONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOPAMINE; JZAD IV 22; NORADRENALIN; SEROTONIN; SERTRALINE; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOSE TIME EFFECT RELATION; DRUG ABUSE; DRUG DISCRIMINATION; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIZATION; FORCED SWIMMING TEST; IN VITRO STUDY; LOCOMOTION; MALE; NONHUMAN; NORADRENALIN BRAIN LEVEL; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; AZA COMPOUNDS; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; COCAINE; CORPUS STRIATUM; DEPRESSION; DISCRIMINATION (PSYCHOLOGY); DOPAMINE; DOPAMINE UPTAKE INHIBITORS; HINDLIMB SUSPENSION; HYPOTHALAMUS; LOCOMOTION; MALE; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SWIMMING; SYNAPTOSOMES;

EID: 78649618505     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174011     Document Type: Article

References (39)

1. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, Newman AH, Javitch JA, Weinstein H, Gether U, et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11:780-789.
2. Breuer ME, Chan JS, Oosting RS, Groenink L, Korte SM, Campbell U, Schreiber R, Hanania T, Snoeren EM, Waldinger M, et al. (2008) The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharmacol 18:908-916.
3. Carter LP and Griffiths RR (2009) Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105 (Suppl 1):S14-S25.
4. D'Aquila PS, Collu M, Gessa GL, and Serra G (2000) The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 405:365-373.
5. Desai RI, Kopajtic TA, French D, Newman AH, and Katz JL (2005a) Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl)methoxy] ethyl}-4-(3-phenylpropyl) piperazine], and benztropine analogs. J Pharmacol Exp Ther 315:397-404. (Pubitemid 41380536)
6. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, and Katz JL (2005b) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25:1889-1893. (Pubitemid 40289393)
7. Drevets WC and Furey ML (2010) Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 67:432-438.
8. El Yacoubi M, Costentin J, and Vaugeois JM (2003) Adenosine A2A receptors and depression. Neurology 61:S82-S87.
9. Holtzman SG (1985) Drug discrimination studies. Drug Alcohol Depend 14:263-282.
10. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
11. Janowsky A, Berger P, Vocci F, Labarca R, Skolnick P, and Paul SM (1986) Characterization of sodium-dependent [3H]GBR-12935 binding in brain: a radioligand for selective labeling of the dopamine transport complex. J Neurochem 46:1272-1276. (Pubitemid 16010982)
12. Katz JL, Kopajtic TA, Agoston GE, and Newman AH (2004) Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther 309:650-660.
13. Koenigs M and Grafman J (2009) The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 201:239-243.
14. Kuhar MJ, Ritz MC, and Boja JW (1991) The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302.
15. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, and Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73:813-823.
16. Lucki I, Dalvi A, and Mayorga AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl) 155:315-322. (Pubitemid 32477289)
17. Paterson NE, Balci F, Campbell U, Olivier BE, and Hanania T (2010a) The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition. J Psychopharmacol doi:10.1177/0269881110364272.
18. Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, and Caldarone B (2010b) Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 95:449-456.
19. Perovic S and Müller WE (1995) Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 45:1145-1148.
20. Pierce RC and Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25:192-216.
21. Prins J, Denys DA, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Groenink L, Olivier B, and Korte SM (2010) The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol 633:55-61.
22. Robinson TE and Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247-291.
23. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905-1917.
24. Salamone JD and Correa M (2009) Dopamine/adenosine interactions involved in effort-related aspects of food motivation. Appetite 53:422-425.
25. Samaha AN and Robinson TE (2005) Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26:82-87.
26. Short PH and Shuster L (1976) Changes in brain norepinephrine associated with sensitization to D-amphetamine. Psychopharmacology (Berl) 48:59-67.
27. Silverman PB and Ho BT (1976) Discriminative response control by psychomotor stimulants. Psychopharmacol Commun 2:331-337.
28. Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, and Lippa A (2006) Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 12:123-134.
29. Skolnick P, Popik P, Janowsky A, Beer B, and Lippa AS (2003) "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci 73:3175-3179.
30. Steketee JD (2005) Cortical mechanisms of cocaine sensitization. Crit Rev Neurobiol 17:69-86.
31. Sunal R, Gümüşel B, and Kayaalp SO (1994) Effect of changes in swimming area on results of "behavioral despair test". Pharmacol Biochem Behav 49:891-896.
32. Weikop P, Egestad B, and Kehr J (2004) Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain. J Neurosci Methods 140:59-65. (Pubitemid 39625853)
33. Willner P (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 134:319-329.
34. Wise RA (2002) Brain reward circuitry: insights from unsensed incentives. Neuron 36:229-240.
35. Wise RA and Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94:469-492.
36. Woolverton WL and Johnson KM (1992) Neurobiology of cocaine abuse. Trends Pharmacol Sci 13:193-200.
37. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, and O'Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587-595.
38. Zhou J, He R, Johnson KM, Ye Y, and Kozikowski AP (2004) Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization. J Med Chem 47:5821-5824. (Pubitemid 39507326)
39. Zisook S, Rush AJ, Haight BR, Clines DC, and Rockett CB (2006) Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 59:203-210. (Pubitemid 43208965)